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Abstract. In Senegal, antimalarial drugs used in treatment and prevention of malaria are one of the main reasons for
the current success in controlling malaria. However, the successful control of malaria is highly dependent on continued
effectiveness of these drugswhichmaybe compromisedby the spread of drug resistance. Therefore, surveillance of drug
resistance in the malaria parasites is essential. The objective of this pilot study was to test the feasibility of routinely
sampledmalaria rapid diagnostic tests (RDTs) at a national scale to assess the temporal changes in themolecular proﬁles
of antimalarial drug resistance markers of Plasmodium falciparum parasites. Overall, 9,549 positive malaria RDTs were
collected from 14 health facilities across the country. A limited random set of RDTs were analyzed regarding Pfcrt gene
polymorphisms at codon 72–76. Overall, a high but varied prevalence (> 50%) of the wild-type CVMNK haplotype was
observed including a higherCVMNKprevalence in the northern part (75%) comparedwith the southern part of the country
(59%). With caution, the study provides a proof of concept that reuse of discarded P. falciparum positive RDTs can be
applied in large-scale surveillance of antimalarial drug resistance.
In Senegal, chloroquine (CQ) was the ﬁrst-line treatment for
uncomplicated malaria until 1998. High rates of CQ treatment
failures and an increased risk of childhood malaria deaths1
prompted Senegalese health authorities to abandon CQ in
2003. Sulfadoxine–pyrimethamine (SP) plus amodiaquine
(AQ) was then introduced as the ﬁrst-line treatment for un-
complicated Plasmodium falciparum malaria despite the fact
that low numbers of SP and AQ treatment failures were
documented in the country when used alone.2–4 However,
because of resistance against widely used antimalarial drugs,
most countries have been forced to introduce artemisinin
combination therapies (ACTs) formalaria treatment. Following
World Health Organization (WHO) recommendation, in 2006,
the Senegalese health authorities changed to ﬁxed dose
combinations of ACTs; artemether–lumefantrine and artesu-
nate plus AQ (depending on availability) for malaria treatment.
In all sub-Saharan African (SSA) countries with endemic
P. falciparummalaria, ACTs have now been implemented and
are highly efﬁcacious and, until now, without showing any
major signs of emergingACT resistance.Despite thedecrease
in malaria burden in SSA, mainly as a result of successful
control interventions such as large-scale distribution of
insecticide-treated bed nets and treatment with ACTs, it is
becoming crucial to identify emerging drug resistance in an
attempt to delay ACT resistance from spreading to SSA from
Southeast Asia where it is evident. Molecular surveillance of
drug resistance inP. falciparumpopulationscould in that aspect
become essential because this could provide an early warning
sign of emergence of ACT resistance before clinical treatment
failures are observed. Geographical mapping of molecular
surveillance data can furthermore detect temporal changes of
resistance, for instance, increased susceptibility to drugs that
have been abandoned due to drug resistance, such as CQ.
In many malaria-endemic areas, less than half of patients
with suspected malaria infections are truly infected with a
malaria parasite.5 Therefore, parasitological conﬁrmation by
microscopy or rapid diagnostic tests (RDTs) of all suspected
malaria cases is recommended by WHO before antimalarial
treatment formalaria positivesarebegun.6,7Accordingly, from
September 2007, through the National Malaria Control Pro-
gram (NMCP), Senegal has implemented the use of RDTs into
the revised national policy for management of febrile ill-
nesses.8 Furthermore, this has the advantage of restricting
ACT use to conﬁrmedmalaria cases only, resulting in reduced
ACT drug pressure and thus limiting the risks of drug re-
sistance development and spread.9
Previous studies on molecular markers of drug resistance
have largely relied on extraction of DNA fromblood ofmalaria-
infected subjects sampled on ﬁlter papers. Such samples
have been obtained through malaria epidemiological or clini-
cal trial studies whereby the ﬁlter papers are sampled as an
integrated activity of these trials. However, because of de-
clining malaria in SSA, it has become increasingly difﬁcult to
obtain parasite-positive samples. Furthermore, the sampling
and resulting molecular data have depended on where these
trials have been executed and have resulted in geographically
sporadic distribution with some regions/sites contributing to
signiﬁcant molecular knowledge whereas others are not rep-
resented at all. Because studies have shown that it is possible
to obtainmolecular data using RDTs,10,11 instead of relying on
trials for sampling of blood for molecular surveillance, routine
sampling, and “recycling” of the positive malaria RDTs at
sentinel sites could be an attractive alternative. Such an ap-
proach is most likely highly cost effective and would poten-
tially create a repository for molecular surveillance. Such
setup would additionally create a sampling and environmen-
tally safe disposal of used RDTs that otherwise would be
thrown away.
The aim of this study was to pilot test a routine sampling
procedure for obtaining used RDTs from sentinel sites
across Senegal and measure the prevalence of single nucle-
otide polymorphisms of one marker of antimalarial drug
resistance, the Pfcrt gene related to CQ resistance in a subset
of samples.
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This study was conducted in 14 health facilities across
Senegal, namely from the southern zone: Saraya, Ke´dougou,
Velingara, and Tambacounda; from the central zone: Kaolack
and Ndoffane; from the western zone: Dakar (including
Gue´diaway and Pikine); and from the northern zone: Richard
Toll, Podor, and Louga (including Sakal health center) (see
Figure 1). All health posts within each district were included in
the study. Before RDT collection, information meetings with
health authorities, including nurses and community health
workers and the NMCP, were held to explain the objectives
and importance of the study. From July 2013 through 2014,
malaria positive RDTs (SD bioline) were collected, and site,
district, gender, age, and month/year of sampling were noted
on each RDT. The collected RDTs were stored into boxes
containing silica gel and shipped monthly to the central lab-
oratory at the Parasitology Department in the University of
Cheikh Anta Diop in Dakar.
Among these, a limited set of positive RDTs were randomly
selected from each health facility and analyzed further re-
garding polymorphisms at codon 72–76 of thePfcrt gene. The
RDTs cassettes were opened using sterile scissors and for-
ceps, and the nitrocellulose strips taken out. The strips were
cut into two pieces, and the portions containing the sample-
blotting site were used for DNA extraction and placed in a
96 deep-well plate following guidelines.12 In between each
sample, the forceps and scissors were washed in ethanol,
burned, and dried on a clean tissue paper to minimize cross-
contamination during sample preparation. DNA extraction
was performed on the portion of strips containing blood using
the Chelex-100 method as previously described.13 For Pfcrt
genotyping at codons 72–76 (only identifying the CVMNK
wild-type and CVIET mutant haplotypes), a nested polymer-
ase chain reaction (PCR), followed by a sequence-speciﬁc
oligonucleotide probe (SSOP)-enzyme-linked immunosor-
bent assay (ELISA), was applied as described.14
Overall, 9,549 (6,000 in 2013 and 3,549 in 2014) positive
malaria RDTs were collected from the health facilities across
the country as shown in Table 1. Some health facilities pro-
videdmoremalaria positive RDTs than other districts, to some
extent reﬂecting differences in levels of transmission between
the districts. Combining the data, malaria, based on the
positive RDTs collected, wasmore prevalent in the southern
zone (N = 4,522) compared with the central (N = 2,947),
western (N = 1,372), and northern zones (N = 708).
In total, the haplotype at codons 72–76 of the Pfcrt gene
using the PCR-SSOP-ELISA was successfully determined in
94.7% (538/572) of samples as shown in Table 1. Overall, a
high but varied prevalence (> 50%) of the wild-type CVMNK
haplotypewasobserved in all examinedhealth facilities. There
was a clear tendency for higher prevalence of the CVMNK
haplotypes in the northern and northwestern part of the
country (for instance, Richard Toll: 74%; Podor: 78%; Louga:
76%, and Dakar: 92%) compared with the southern part
(Tambacounda: 53% and Ke´dougou: 61%) though, Ve´lingara
was at 68% (see Figure 1).
Increasing prevalence of CQ sensitive P. falciparum pop-
ulations has been shown before in Senegal,15 and the data
presented here complement these ﬁndings, and eventually,
CQmaybeattempted tobe reintroducedagain in combination
with another drug and, for instance, only be given to certain
patient groups. However, the wide differences observed
across the country underscores the validity (and necessity) of
continuedmonitoring ofmolecularmarkers if themarkers shall
become operational and support drug policy.
In this study, we provided a proof of concept that reuse
of discarded P. falciparum positive RDTs can be applied in
FIGURE 1. Prevalence of Pfcrt haplotypes (CVMNK) across Senegal. Blue: Pfcrtwild-type (CVMNK) haplotype also noted as actual percentage.
Red: Pfcrtmutant (CVIET) haplotype. This ﬁgure appears in color at www.ajtmh.org.
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large-scale surveillance of antimalarial drug resistance. Thus,
sampling of these positive RDTs could provide a sample set in
amagnitudeandgeographical distribution necessary to follow
the development of drug resistance at a country or even on a
multicountry level. Such data may eventually support drug
policy authorities in decisions regarding choice of drugs and
possibly limit the time between when a change in policy is
necessary and when such a change actually is implemented.
Furthermore, the RDT sampling procedure is as well a much
cheaper approach than establishing procedures based on
designated sampling of ﬁlter papers as theseRDTsare already
available. Lastly, the alternative reuse of RDTs furthermore
deals with the increasing waste problem arising from the in-
creasing use of RDTs.
However, there are some points of caution before RDTs
sampling, and molecular analyses can be established as a
routine procedure to provide essential data on antimalarial
drug resistance. Despite that we were able to successfully
genotype 94.7% of the samples, further studies using a larger
batch of positive RDTs in subsequent experiments have not
been as successful and less than 50% of the positive RDTs
were PCRpositive (data not shown). One reason for this is that
the sampling and storage procedure (storage at room tem-
perature with silica gel until use) could have hampered effec-
tive DNA extraction, and only RDT positives with high
parasitemia (and thus large quantity of P. falciparum DNA)
resulted in PCR positives. Possibly, the longer time the RDTs
are stored (at high room temperatures) the lower is the chance
to obtain successful PCRs. Preliminary data do suggest that
long-term storage can decrease sensitivity of the RDTs for
molecular analyses.
If this obstacle is solved, the molecular data should
eventually provide crucial information that will aid drug
policymakers. However, the data have to be interpreted and
available soon after sampling which is usually not the case.
For instance, between sampling and publication of molec-
ular data on antimalarial drug resistance others have shown
typically that there is a lag phase of 5 years.16 Thus, rapid
assessment and provision of data (and not necessary
awaiting scientiﬁc publication) are necessary if the molec-
ular data should become operational. We used the PCR-
SSOP-ELISA to obtain data, and although simple and
relatively high-throughput, alternative methodologies us-
ing, for instance, next-generation sequencing platforms
would, in particular, be important to implement as much
focus should be on sequencing the K13 gene associated
with ACT resistance.17,18
Lastly, as no guidelines exist on how often surveillance
surveys should be undertaken and what coverage of sentinel
sites is sufﬁcient to provide operational molecular data to guide
antimalarial drug policy makers, this needs to be explored.
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